Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.26 -0.47 (-0.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
7 Blue-Chip Stocks to Buy for Capital Preservation
These are the low-beta blue-chip stocks to buy as they represent companies with a strong balance sheet and healthy cash flow potential. 
Via InvestorPlace
3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030
These historically profitable dividend-paying stocks are ideal for risk-averse investors wanting to take advantage of a bear market discount. 
Via The Motley Fool
Nvidia Ramps Up Artificial Intelligence Offerings Amid AI's 'iPhone Moment'
Nvidia on Tuesday demonstrated how its technology is advancing artificial intelligence in myriad industries. Nvidia stock has soared in 2023. 
Via Investor's Business Daily
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
2 Steady Stocks to Buy and Hold Forever
Investing in these companies can help you sleep easy at night. 
Via The Motley Fool
P/E Ratio Insights for AstraZeneca
Via Benzinga
A Look Into AstraZeneca's Debt
Via Benzinga
AstraZeneca's Debt Overview
Shares of AstraZeneca Inc. (NASDAQ:AZN) fell by 5.41% in the past three months. Before having a look at the importance of debt, let's look at how much debt AstraZeneca has. 
Via Benzinga
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D... 
Via Benzinga
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
Via Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
Via Benzinga
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy With $400 Right Now
A reasonably small amount of money can go a long way when it's invested in innovative businesses. 
Via The Motley Fool
AstraZeneca Plc (AZN) Q4 2022 Earnings Call Transcript
AZN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
2 Top Biotech Stocks to Buy Right Now
These two companies each pay market-beating dividends to shareholders. 
Via The Motley Fool
AstraZeneca Stock Jumps As Upbeat Guidance Offsets Mixed Quarterly Report
The company's guidance palliated concerns of high expenses this year, an analyst said. 
Via Investor's Business Daily
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry. 
Via InvestorPlace
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
Via Benzinga
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
It's not a good day for investors when their company reports a shocking plunge into the red. 
Via The Motley Fool
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday. 
Via The Motley Fool
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
AstraZeneca Earnings Preview
Via Benzinga
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
Via Benzinga
AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab
Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER). 
Via Talk Markets
US Stocks On Recovery Course As Earnings Lend Support: Fed's Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst
The see-sawing mood in the market continues as Fed’s data dependency creates volatility. The index futures point to a solidly higher opening on Thursday, signaling a reversal in the sentiment seen in... 
Via Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years. 
Via The Motley Fool
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
Danaher Corporation (NYSE: DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE: CTLT). 
Via Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.